CD30 CAR-T cells in combination with anti-PD-1 camrelizumab in relapsed/refractory CD30+ lymphomas - PubMed
5 days ago
- #CD30
- #CAR-T
- #lymphoma
- Study on CD30 CAR-T cells combined with anti-PD-1 camrelizumab for relapsed/refractory CD30+ lymphomas.
- Ethical approval obtained from the First Affiliated Hospital of Nanchang University and Tongji Medical College, Huazhong University of Science and Technology.
- No conflicts of interest declared by the authors.
- Findings partially presented at the ASH (2024) annual meeting.
- References include historical perspectives on CD30 biology and therapeutic targeting, CD30-targeted antibody therapy, and FDA approvals of CAR-T cell therapies.